Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Aripiprazole lauroxil (Aristada) is indicated for the treatment of schizophrenia in adults and has a relatively favorable safety profile, particularly regarding motor side effects and metabolic adverse effects. It is associated with reduced serum prolactin levels and a reduced QTc interval, distinguishing it from many antipsychotics prone to prolonging this interval.
• Four systematic reviews/meta-analyses provided an extensive comparison of Aristada in terms of safety and effectiveness specifically for treating schizophrenia in adults.
• Compared to other antipsychotics, both monohydrate and lauroxil formulations of aripiprazole LAI have demonstrated efficacy in reducing relapses/recurrences compared to placebos or lower doses. They also improved symptomatology during acute psychotic episodes, indicating that Aristada can be effective for long-term stabilization as well as during acute phases.
• Long-acting injectable forms such as Aristada offer infrequent dosing intervals of up to every 8 weeks, providing an advantage especially for individuals who struggle with adhering to daily oral medication regimens, potentially improving treatment adherence outcomes within this subgroup.
• In terms of preventing relapse and hospitalization, LAIs, including aripiprazole lauroxil, are generally found comparable with Oral Antipsychotics (OAPs). Quality of life, functioning tolerability appeared similar between individuals treated with LAIs and those with OAPs, but higher patient satisfaction and service engagement were noted among those using LAIs like Aristada.
• While these studies provide a general overview of its safety and effectiveness, specific subgroup considerations, e.g., age, sex, ethnic groups, were not detailed, suggesting a need for future research to address potential variations in response.